Home

The Domino Effect

Daniel Carlson -
6
This week, in what was a somewhat nostalgic moment for me, Cryoport (CYRX)'s earnings hit the newswire. For long time readers of TW, you...
Read more

Trading Alert, August 5th, 2022

Daniel Carlson -
0
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Trading Alert, August 2nd, 2022

Daniel Carlson -
0
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Micros Rallied in July, Can It Continue?

Daniel Carlson -
3
Just when it's hottest in NY, and all the bankers have taken off for the Hamptons, we get to earnings season for the micro-caps...
Read more

Spectra7 Announces $8.0 Million Convertible Debenture Financing; Closing of First Tranche

Daniel Carlson -
0
TW's Take: this is great news for the company as it takes funding risk off the table, allowing them to focus on their rapidly...
Read more

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to...

Daniel Carlson -
0
TW's Take: positive progress for this totally beaten down stock. When will the market wake up to this opportunity? MBIO is a partner company...
Read more

Dog Days of Summer

Daniel Carlson -
1
Markets had a solid week but Friday was a classic example of what can happen during the slow summer months. Liquidity dries up and,...
Read more

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology

Daniel Carlson -
2
TW's Take: Anixa continues to move this program forward. Expect compelling data from the ongoing phase 1 trial sometime late in 2022. SAN JOSE, Calif., July...
Read more

Trading Alert, July 19th, 2022

Daniel Carlson -
2
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Taking the Long View on TFF

Daniel Carlson -
0
This week my group had a Zoom call with TFF Pharma (TFFP). Over the past year TFF has become a very polarizing stock. There...
Read more

TFF Pharmaceuticals Expands R&D Operations with New Austin Facility

Daniel Carlson -
3
TW's Take: this quote, "as many of our partnered programs move to clinical evaluation", is what the investment community is looking for. When TFF...
Read more

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for...

Daniel Carlson -
0
TW's Take: this trial has the potential to change the perception of Lantern as success here would immediately revalue this company. Results expected sometime...
Read more

Catalysts Aplenty, a 2nd Half Preview

Daniel Carlson -
1
It's tough to read too much into a small sample size but the first week of July's stock performance has me thinking that my...
Read more

Texas Court Grants ParkerVision Motion to Add Willfulness to Intel Complaint

Daniel Carlson -
2
TW's Take: good progress for Parker as the court case against Intel get closer and closer... JACKSONVILLE, FL / ACCESSWIRE / July 6, 2022 /...
Read more

enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering...

Daniel Carlson -
0
TW's Take: important step towards full coverage of the Venovalve. NVNO trades below cash, is funded through approval, and the product will likely be...
Read more

Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at...

Daniel Carlson -
0
DUBLIN, Ireland, and Boston MA, July 7, 2022,  Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments...
Read more

June in Review

Daniel Carlson -
3
Okay, so I lied. I said that I wouldn't have a newsletter this week but couldn't help myself and here we are with a...
Read more

This Week’s Newsletter

Daniel Carlson -
0
In a welcome, and overdue respite, markets rallied this past week. As we have been suggesting would be the case, the relief rally was...
Read more

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

Daniel Carlson -
0
TW's Take: positive news for AMYT as they now have a 4th product on the market. This is a sleeper stock with solid growth...
Read more

Spectra7 Expands Availability of Active Copper Cables with new Design-in with ACES to Deliver...

Daniel Carlson -
0
TW's Take: SPVNF is well positioned in several growing markets and, as supply chain issues alleviate, sales should begin to accelerate rapidly. SAN JOSE, CA...
Read more

Become a TW Research Member

All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.

For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $500 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.

SIGN ME UP

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

© TW Research Group LLC
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.